Development of a Melanin-Based High-Performance Liquid Chromatography Stationary Phase and Its Use in the Study of Drug-Melanin Binding Interactions
✍ Scribed by H. Ibrahim; A.F. Aubry
- Publisher
- Elsevier Science
- Year
- 1995
- Tongue
- English
- Weight
- 476 KB
- Volume
- 229
- Category
- Article
- ISSN
- 0003-2697
No coin nor oath required. For personal study only.
✦ Synopsis
Drug-melanin interactions were studied using a melanin-based HPLC column. Two approaches were chosen for the preparation of the stationary phases: covalent coupling of synthetic L-dopa melanin and in situ polymerization of L-dopa. Retention of a series of phenothiazines on melanin-based stationary phases was attributed to binding to melanin. Frontal affinity chromatography experiments on one melanin-based column allowed us to calculate the affinity and binding capacity of chlorpromazine and promethazine. A competition was observed between chlorpromazine and haloperidol which was qualitatively consistent with previously described results. Data indicated that the interaction was not a simple competition at one site.
v) 1995 Academic Press, Inc.
📜 SIMILAR VOLUMES
A sensitive enantioselective high-performance chromatographic (HPLC) method was developed and validated to determine low levels of (-)-R and (+)-S-albuterol in plasma. Baseline resolution was achieved by using a teicoplanin-based chiral stationary phase with a polar organic mobile phase consisting o
## Abstract A quick and sensitive reversed‐phase HPLC method has been developed for the analysis of 2′‐β ‐fluoro‐2′,3′‐dideoxy adenosine (F‐ddA), the acid‐stable anti‐AIDS drug, and its metabolite 2′‐fluoro‐2′,3′‐dideoxy inosine (F‐ddI) in human plasma using polyfluorinated stationary phase column
E‐3810, 6‐[[7‐[(1‐aminocyclopropyl)methoxy]‐6‐methoxy‐4‐quinolyl]oxy]‐__N__‐methyl‐naphthalene‐1‐carboxamide, is a novel, potent, dual inhibitor of vascular endothelial growth factor and fibroblast growth factor receptors with antiangiogenic properties, now under early clinical evaluation as an anti
## Abstract CEP‐18770, [(1__R__)‐1‐{[(2__S__,3__R__)‐3‐hydroxy‐2‐{[(6‐phenyl‐2‐pyridinyl)carbonyl]amino}butanoyl]amino}‐3‐methylbutyl]boronic acid, is a novel proteasome inhibitor, now under early clinical evaluation as an anticancer agent. To investigate its clinical pharmacokinetics, a high‐perfo